Q1 EPS Estimates for Mural Oncology Cut by HC Wainwright

Mural Oncology plc (NASDAQ:MURA) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Mural Oncology in a report issued on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($2.13) per share for the quarter, down from their previous estimate of ($2.05). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the prior year, the firm earned ($3.57) earnings per share.

Mural Oncology Stock Up 3.9 %

Shares of NASDAQ:MURA opened at $4.23 on Monday. The company has a market cap of $72.87 million, a P/E ratio of -0.46 and a beta of 3.66. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.12. The business has a fifty day simple moving average of $3.90 and a 200-day simple moving average of $3.61.

Institutional Investors Weigh In On Mural Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in MURA. Commerce Bank purchased a new stake in shares of Mural Oncology in the third quarter valued at $39,000. FMR LLC grew its position in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares during the period. Jane Street Group LLC purchased a new stake in Mural Oncology during the fourth quarter valued at about $68,000. Two Sigma Advisers LP purchased a new stake in Mural Oncology during the fourth quarter valued at about $84,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Mural Oncology during the fourth quarter valued at about $94,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.